Development and Characterization of Biopolymers Based Multiparticulate System: Potential Carriers for Controlled and Targeted Drug Delivery

Wasim Akram, Navneet Garud 1

8th WCPSDM.2021. APR.Published Online 18 APR 2021

Abstract : Oral drug delivery systems which are designed to target the colon require protecting the drug during its transit through the stomach and small intestine to reach the desired site. Many approaches have been designed for colon precise drug delivery. They comprise systems using pH sensitive and biodegradable polymers as enteric which are based either on transit time or increasing the luminal pressure within the GIT and enzymatically controlled delivery systems. In contrast to conventional single unit dosage forms, multiparticulate systems have a number of advantages, such as more predictable rate of gastric emptying and less localized adverse effects. Naturally occurring polymers gain a lot of attention for drug targeting to the colon, because these polymers are found in plenty, are economical and exist in a variety of structures with different properties. They can be simply chemically and biochemically modified and are very much stable, safe, non-toxic, hydrophilic, gel-forming, and in addition, biocompatible and biodegradable. Our current approach is to target the colon with minimum loss of active therapeutic and less toxic effect in the upper part of GIT. So, in the proposed study, Biopolymer decorated Nanoparticulate system bearing mesalamine drug will be prepared to target the colon to treat ulcerative colitis and evaluated for the treatment response. The overall aim of the project is to design a highly précised drug delivery system with increased therapeutic and targeting efficiency for the treatment of ulcerative colitis. The proposed system will provide the site-specific drug targeting of therapeutics, discriminate drug distribution, less or no toxicity of drug, reducing dosing frequency as compared to other conventional formulation and also reduction in fluctuation of drug level at the site of action by controlled release, improving performance of bioactive compound in terms of efficacy, safety and improved patient compliance by developing a potential carrier for controlled drug delivery and also provides economic benefit for both consumer and manufacturer.